Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443122 in severe COVID-19
NCT04469621Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jul 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SAR443122 with Placebo (2 arms). Primary endpoint: Relative change from baseline in C-reactive protein at 7 days. Started Jul 2020; status: completed.
02
Drugs
eclitasertib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04469621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04469621.